ASI-Life Sciences commissioned a CFD study of our imPULSE single-use mixing systems to predict and characterize the mixing performance of the systems across small, medium and large vessels and fluid viscosities. One characterization from the study as you will see in Figure 1 of the poster was the rate at which the momentum from the mixing disc transferred through the fluid. As you can see in the Figure within 5 seconds, fluid motion was achieved in the 250 L, 1,500…

The implementation of single-use technologies for pharmaceutical product development continues to gain momentum; this trend is due to the advantages of increased flexibility, speed of implementation and lower capital investment. In particular, they are seen as a means to accelerate the production of material for clinical trials. However, a primary concern regarding the use of such technologies is the impact and level of leachables in the final drug substance. Typically this concern is addressed through a risk assessment utilizing extractable…

Frozen storage is commonly performed and enables manufacturing process flexibility, long-term product stability and minimizes logistics challenges.  While single-use containers are available for storage and transport of frozen products, some require a significant investment while others don’t offer the necessary support and protection. Using films and bags not designed for frozen storage applications can be detrimental.   Charter Medical recently developed a new family of single-use frozen storage and transport solutions. The Freeze-Pakâ„¢ STS (FP-STS) bio-containers and supporting secondary single-use…

Mammalian cells are a widely used expression platform for the production of recombinant therapeutic proteins or viral particle-based vaccines since they typically perform appropriate protein post-translational modifications and authentic viral particle assembly. Of the available mammalian cells, CHO and HEK 293 are some of the most industrially relevant cell lines because they are cGMP compliant and are able to grow in suspension in a variety of serum-free media. Of note, production of human therapeutics in mammalian cell culture has become…

For autologous T cell therapy to be effective, T cells sampled from a patient need to be grown in sufficient quantity before being injected back. The typical cell number required for an 80 kg patient is 8.109 cells. Achieving such a dose with T flasks, while maintaining cell health, poses logistical challenges that can become intractable when the number of patients rises. This is why the Xuriâ„¢ Cell expansion system W5, a rocking platform which enables automated high cell density…

Lymphocytes, expanded for clinical use, often consist of a small selected starting population, which requires multiple rounds of replication to achieve therapeutic doses. By using perfusion culture with the WAVE Bioreactor 2/10 System, high cell density cultures which are sufficient for therapeutic doses, can be generated. The Cellbagâ„¢ bioreactors, used together with the WAVE system, are functionally closed, single-use bioreactors that are delivered pre-sterilized and suitable for cGMP production. Perfusion is automatically maintained by the WAVE system, which removes metabolites…

This poster presents a study on the performance of two types of single-use in an antibody fed-batch process. The bioreactors were the stirred tank Xcellerexâ„¢ XDR-200 bioreactor and the rocking ReadyToProcess WAVEâ„¢ 25 bioreactor system. The cell line used was a CHO-DG44 derived antibody‑producing cell line and the base medium and feeds were from the ActiCHOâ„¢ media platform. The results from the parallel cultures presented in figures 3,4 and 5 show that cell growth, productivity and metabolism were very similar.…